Medical Condition News

RSS

Unhealthy behaviors contribute to excessive number of premature deaths in U.S.

The standard American diet, combined with inactivity and other unhealthy lifestyle behaviors, contributes to an excessive number of premature deaths in this country, according to leading preventive cardiology experts speaking at the American College of Cardiology's Fourth Annual Heart of Women's Health Conference in Washington, D.C.

9 Feb 2010

Seven-day exercise plan for reducing cancer risk

Being active for at least 30 minutes every day reduces your risk of developing some types of cancer. Fitness experts at The University of Texas M. D. Anderson Cancer Center have designed an exclusive exercise plan based on this evidence that will fit into almost anyone's lifestyle.

9 Feb 2010

Boston researchers identify new mechanism that inhibit tumor growth in mice

A team of researchers, led by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, has identified a new type of cellular senescence (i.e., irreversible arrest of cell growth) and determined a way to enhance it to suppress prostate tumor development and growth in mice.

9 Feb 2010

FDA approves Lupin Pharmaceuticals' Amlodipine/Benazepril capsules

Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules. Commercial shipments of the product have already commenced.

9 Feb 2010

New revolutionary treatment for patients suffering from movement disorders

Deep Brain Stimulation (DBS), a new treatment being offered at Geisinger Medical Center (GMC) and Geisinger Wyoming Valley Medical Center (GWV), can dramatically reduce symptoms of movement disorders.

9 Feb 2010

FDA approves Sagent Pharmaceuticals' labetalol HCl injection for severe hypertension

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has received FDA approval of labetalol hydrochloride (HCl) injection, USP, commonly used to control severe hypertension. The product will be available in two vial sizes – 100 mg per 20 mL and 200 mg per 40 mL, multi-dose vials.

9 Feb 2010

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

Cancer Research UK's commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday).

9 Feb 2010

Dimebon drug associated with improved cognitive function in patients with Huntington's disease

An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition. That is the conclusion of a study published today in the Archives of Neurology.

9 Feb 2010

Tax on sugared drinks loses appeal, tanning salons still fighting

Los Angeles Times: "Only months ago, supporters of the soda tax saw it as an idea whose hour was near. The sheer magnitude of the medical cost of obesity added urgency to the issue ... But opponents questioned any link between sugary drinks and obesity, and expressed concern about a slippery slope of taxes on other products. Proponents, meanwhile, thought a tax that drove down consumption while raising money for health care seemed like a natural with Democrats controlling Congress."

9 Feb 2010

Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.

9 Feb 2010

Study reveals people with anorexia nervosa have increased fat content in their bone marrow

People with anorexia nervosa, paradoxically, have strikingly high levels of fat within their bone marrow, report researchers at Children's Hospital Boston. Their findings, based on MRI imaging of the knees of 20 girls with anorexia and 20 healthy girls of the same age, appear in the February issue of the Journal of Bone and Mineral Research.

9 Feb 2010

Genta commences Phase 2 trial of tesetaxel on first subject

Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company’s newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta’s experience in melanoma clinical research.

9 Feb 2010

A novel way to identify color choice in healthy, anxious and depressed individuals

People with anxiety and depression are most likely to use a shade of gray to represent their mental state. Researchers writing in the open access journal BMC Medical Research Methodology describe the development of a color chart, The Manchester Color Wheel, which can be used to study people's preferred pigment in relation to their state of mind.

9 Feb 2010

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS). Under the new agreement, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech will receive a higher royalty rate for sales in these territories compared to the royalty rate set under the original licensing agreement signed in 2004 for sales in the rest of the world.

9 Feb 2010

FDA approves Amneal Pharmaceuticals' Tramadol/APAP tablets

Amneal Pharmaceuticals is pleased to announce that it received U.S. FDA approval to manufacture combination Tramadol HCl in 37.5 mg strength and Acetaminophen in 325 mg strength (Tramadol/APAP) in tablet form effective December 9, 2009. Amneal’s generic is an AB-rated, therapeutically equivalent alternative to Ultracet® (a licensed trademark of Ortho-McNeil Janssen). U.S. sales of Tramadol/APAP were $61 MM according to June 2009 IMS Health market data.

8 Feb 2010

QIAGEN acquires global licence for PI3K gene to develop real-time-PCR and endpoint PCR assays

QIAGEN today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.

From QIAGEN Manchester Limited 8 Feb 2010

Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.

8 Feb 2010

Hand amputation distorts visuospatial perception of the action space

We know exactly where an object is when we say it is "within the reach of our hand." But if we don't have a hand, can we still see the object just where it is?

8 Feb 2010

Memory complaints: Effectiveness of Non-pharmacological interventions

A meta-analysis published in the current issue of Psychotherapy and Psychosomatics by Swiss investigators B. Metternich and associates indicates the effectiveness of non pharmacological interventions on memory complaints.

8 Feb 2010

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia in China.

8 Feb 2010

Medical Condition News

Unhealthy behaviors contribute to excessive number of premature deaths in U.S.

Seven-day exercise plan for reducing cancer risk

Boston researchers identify new mechanism that inhibit tumor growth in mice

FDA approves Lupin Pharmaceuticals' Amlodipine/Benazepril capsules

New revolutionary treatment for patients suffering from movement disorders

FDA approves Sagent Pharmaceuticals' labetalol HCl injection for severe hypertension

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

Dimebon drug associated with improved cognitive function in patients with Huntington's disease

Tax on sugared drinks loses appeal, tanning salons still fighting

Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency

Study reveals people with anorexia nervosa have increased fat content in their bone marrow

Genta commences Phase 2 trial of tesetaxel on first subject

A novel way to identify color choice in healthy, anxious and depressed individuals

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

FDA approves Amneal Pharmaceuticals' Tramadol/APAP tablets

QIAGEN acquires global licence for PI3K gene to develop real-time-PCR and endpoint PCR assays

Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study

Hand amputation distorts visuospatial perception of the action space

Memory complaints: Effectiveness of Non-pharmacological interventions

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News